ZA201003906B - Treatment of colon disease or prevention of colorectal carinoma with imidazoquinoline derivatives - Google Patents

Treatment of colon disease or prevention of colorectal carinoma with imidazoquinoline derivatives

Info

Publication number
ZA201003906B
ZA201003906B ZA2010/03906A ZA201003906A ZA201003906B ZA 201003906 B ZA201003906 B ZA 201003906B ZA 2010/03906 A ZA2010/03906 A ZA 2010/03906A ZA 201003906 A ZA201003906 A ZA 201003906A ZA 201003906 B ZA201003906 B ZA 201003906B
Authority
ZA
South Africa
Prior art keywords
carinoma
colorectal
prevention
treatment
colon disease
Prior art date
Application number
ZA2010/03906A
Other languages
English (en)
Inventor
Ursula Petzold
Istvan Szelenyi
Joachim Maus
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201003906(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab filed Critical Meda Ab
Publication of ZA201003906B publication Critical patent/ZA201003906B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
ZA2010/03906A 2008-01-15 2010-06-01 Treatment of colon disease or prevention of colorectal carinoma with imidazoquinoline derivatives ZA201003906B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US645908P 2008-01-15 2008-01-15
PCT/EP2008/011088 WO2009089900A1 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
ZA201003906B true ZA201003906B (en) 2011-03-30

Family

ID=40419193

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/03906A ZA201003906B (en) 2008-01-15 2010-06-01 Treatment of colon disease or prevention of colorectal carinoma with imidazoquinoline derivatives

Country Status (15)

Country Link
US (1) US8008319B2 (enExample)
EP (1) EP2237780A1 (enExample)
JP (1) JP2011509956A (enExample)
CN (1) CN101909624A (enExample)
AU (1) AU2008347400B2 (enExample)
BR (1) BRPI0822002A2 (enExample)
CA (1) CA2708559C (enExample)
EA (1) EA018579B1 (enExample)
GE (1) GEP20125605B (enExample)
IL (1) IL205819A (enExample)
MX (1) MX2010007699A (enExample)
NZ (1) NZ586161A (enExample)
UA (1) UA101339C2 (enExample)
WO (1) WO2009089900A1 (enExample)
ZA (1) ZA201003906B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004706A (es) 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
EP3092255A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating egfr expressing tumors
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200019226A (ko) 2017-06-23 2020-02-21 버디 바이오파마슈티칼즈, 인크. 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078547C1 (ru) * 1995-11-28 1997-05-10 Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ Способ лечения полипоза желудка и двенадцатиперстной кишки
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
JP2007511575A (ja) * 2003-11-21 2007-05-10 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ阻害剤としての１ｈ−イミダゾキノリン誘導体

Also Published As

Publication number Publication date
AU2008347400B2 (en) 2014-12-11
EA201001164A1 (ru) 2010-12-30
EA018579B1 (ru) 2013-09-30
NZ586161A (en) 2012-05-25
EP2237780A1 (en) 2010-10-13
CA2708559C (en) 2015-10-06
IL205819A0 (en) 2010-11-30
BRPI0822002A2 (pt) 2015-10-13
WO2009089900A1 (en) 2009-07-23
UA101339C2 (ru) 2013-03-25
US20090182005A1 (en) 2009-07-16
CA2708559A1 (en) 2009-07-23
CN101909624A (zh) 2010-12-08
MX2010007699A (es) 2010-08-04
US8008319B2 (en) 2011-08-30
JP2011509956A (ja) 2011-03-31
IL205819A (en) 2013-02-28
AU2008347400A1 (en) 2009-07-23
GEP20125605B (en) 2012-08-10

Similar Documents

Publication Publication Date Title
IL205819A0 (en) Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
AP2011005943A0 (en) Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use.
NO2016023I1 (no) Glycerol fenylbutyrat
ZA201103255B (en) Treatment of acute lymphoblastic leukemia
LT2229369T (lt) 6,7-dialkoksi-chinazolino dariniai, tinkami panaudoti su vėžiu susijusių susirgimų gydymui
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
IL218971A0 (en) Sulfoxide derivatives for the treatment of tumours
EP2081950A4 (en) EXPRESSION PROFILES ASSOCIATED WITH IRINOTECAN TREATMENT
IL207520A0 (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
ZA201004333B (en) Treatment of oral pharyngeal dysphagia
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL200966A0 (en) Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
EP2164494A4 (en) Methods of Treatment
GB0812913D0 (en) Therapeutic compounds and their use
GB0723100D0 (en) Treatment of HFnEF
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
GB2460445B (en) Treatment of ringworm
SI2330892T1 (sl) Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak
IL207753A0 (en) Substituted 4-aminocyclohexane derivatives for the treatment of pain
GB0819543D0 (en) Treatment of proteostatic disease
GB0817859D0 (en) Treatment of proteostatic disease
GB0809319D0 (en) The treatment of puritus